|
| Exchange Received Time 12/07/2018 16:31:35 Exchange Disseminated Time 12/07/2018 16:31:41 Time Taken 00:00:06 | Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we, hereby, inform you that the Company has received a letter dated 11th July, 2018 from the Food and Drug Administration (FDA) authorities directing, inter alia, not to manufacture a key product till deciding of the matter. The Company has been given an opportunity to be heard and is taking necessary steps to suitably reply to the said letter. The product is being manufactured and marketed by the Company as also supplied to a Pharma Company on Principal to Principal basis. The Company, being aggrieved by the developments, has filed a Writ Petition in the Hon'ble Delhi High Court in this connection and the same has been admitted by the Hon'ble Delhi High Court.
This may be taken as a disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015.
The Company will keep the Stock Exchange informed of any further developments in this matter.
|
|
|